Distinct MicroRNA alterations characterize high- and low-grade bladder cancer

Cancer Research

Volumn 69, Issue 21, 2009, Pages 8472-8481

  Catto, James W F ^a   Miah, Saiful ^a   Owen, Helen C ^a   Bryant, Helen ^a   Myers, Katie ^a   Dudziec, Ewa ^a   Larré, Stéphane ^b   Milo, Marta ^d   Rehman, Ishtiaq ^a   Rosario, Derek J ^a   Di Martino, Erica ^e   Knowles, Margaret A ^e   Meuth, Mark ^a   Harris, Adrian L ^c   Hamdy, Freddie C ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DICER; EXPORTIN 5; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MICRORNA; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER GRADING; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; DEAD-BOX RNA HELICASES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RIBONUCLEASE III; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 70350536585     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0744     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23: 4602-4608 (Pubitemid 46224062)
3. Herr HW, Dotan Z, Donat SM, Bajorin DF. Defining optimal therapy for muscle invasive bladder cancer. J Urol 2007;177:437-443 (Pubitemid 46075130)
4. Catto JW, Azzouzi AR, Rehman I, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 2005;23:2903-2910 (Pubitemid 46224108)
5. Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006;27:361-373
6. Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 2008;9:219-230 (Pubitemid 351301826)
7. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-833 (Pubitemid 40839734)
8. Voorhoeve PM, le Sage C, Schrier M, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006;124:1169-1181
9. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-2261 (Pubitemid 43271657)
10. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299:425-436
11. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008;13:48-57.
12. Gottardo F, Liu CG, Ferracin M, et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007;25:387-392 (Pubitemid 47362758)
13. Neely LA, Rieger-Christ KM, Neto BS, et al. A micro-RNA expression ratio defining the invasive phenotype in bladder tumors. Urol Oncol 2008, Epub.
14. Catto JW, Rosario DJ. The road to cystectomy: who, when and why? Eur Urol, EAU Update series 2005;3: 171-179
15. Southgate J, Hutton KA, Thomas DF, Trejdosiewicz LK. Normal human urothelial cells in vitro: proliferation and induction of stratification. Lab Invest 1994; 71:583-594 (Pubitemid 24338167)
16. Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005;33:e179. (Pubitemid 41806407)
17. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008;455: 58-63.
18. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature 2008;455:64-71.
19. Chapman EJ, Hurst CD, Pitt E, Chambers P, Aveyard JS, Knowles MA. Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway. Oncogene 2006;25:5037-5045 (Pubitemid 44246362)
20. Tomlinson DC, L'Hote CG, Kennedy W, Pitt E, Knowles MA. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines. Cancer Res 2005;65:10441-10449 (Pubitemid 41743738)
21. Schmittgen TD, Lee EJ, Jiang J, et al. Real-time PCR quantification of precursor and mature microRNA. Methods 2008;44:31-38 (Pubitemid 350297984)
22. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-5121 (Pubitemid 32397092)
23. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002;99: 6567-6572 (Pubitemid 34526173)
24. Wild PJ, Herr A, Wissmann C, et al. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res 2005;11: 4415-4429 (Pubitemid 40825632)
25. Papagiannakopoulos T, Shapiro A, Kosik KS. Micro-RNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 2008;68:8164-8172
26. Huang Q, Gumireddy K, Schrier M, et al. The micro- RNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008;10:202-210 (Pubitemid 351194050)
27. Dhawan D, Hamdy FC, Rehman I, et al. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathol 2006;209:336-343 (Pubitemid 43997742)
28. Lujambio A, Ropero S, Ballestar E, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007;67:1424-1429 (Pubitemid 46383366)
29. Saito Y, Liang G, Egger G, et al. Specific activation of microRNA-127 with downregulation of the protooncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006;9:435-443 (Pubitemid 43832188)
30. Catto JW, Hartmann A, Stoehr R, et al. Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. J Urol 2006;175:2323-2330 (Pubitemid 43668524)
31. Chiosea S, Jelezcova E, Chandran U, et al. Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol 2006;169:1812-1820 (Pubitemid 351182010)
32. Chiosea S, Jelezcova E, Chandran U, et al. Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res 2007;67:2345-2350 (Pubitemid 46424256)
33. Merritt WM, Lin YG, Han LY, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008;359:2641-2650
34. Bandres E, Cubedo E, Agirre X, et al. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006;5:29. (Pubitemid 44264064)
35. Blaveri E, Brewer JL, Roydasgupta R, et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 2005;11: 7012-7022 (Pubitemid 41428761)
36. Dyrskjot L, Kruhoffer M, Thykjaer T, et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004;64:4040-4048 (Pubitemid 38697320)
37. L'Hote CG, Knowles MA. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res 2005;304:417-431
38. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006;24: 778-789 (Pubitemid 46622045)
39. Aaboe M, Birkenkamp-Demtroder K, Wiuf C, et al. SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res 2006;66:3434-3442
40. Datta J, Kutay H, Nasser MW, et al. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 2008;68: 5049-5058
41. Lujambio A, Calin GA, Villanueva A, et al. A micro-RNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 2008;105: 13556-13561
42. Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA, Clark SJ. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet 2006;38:540-549